GemPharmatech (SH:688046) Zheng Quan Zhi Xing·2025-08-22 16:24Group 1 - The board of directors of Jiangsu Jicui Yaokang Biotechnology Co., Ltd. held its 13th meeting of the second session on August 21, 2025, with all 9 directors present, including 3 independent directors [1] - The board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's financial status and operational results [2] - The board also approved a special report on the management and actual use of raised funds for the first half of 2025, ensuring compliance with relevant laws and regulations [2] Group 2 - The board reviewed and approved the semi-annual evaluation report of the "Quality Improvement and Efficiency Enhancement Action Plan for 2025," aimed at promoting sustainable development and protecting shareholder interests [3] - A profit distribution plan was approved, proposing a cash dividend of RMB 0.30 per 10 shares (tax included), with no stock dividends or capital reserve transfers [3] - The board decided to cancel the supervisory board and amend the company’s articles of association to enhance governance structure, which complies with legal requirements [4] Group 3 - The board approved the addition and revision of certain governance systems to further improve the company's governance structure and ensure compliance with relevant laws [5] - A proposal to supplement a non-independent director to the board and adjust the strategic committee was approved, with the candidate being Mr. Liu Dan [6] - The board agreed to use its own funds to pay for certain project expenses and later replace these with raised funds, ensuring financial flexibility [6] Group 4 - The board proposed to convene the second extraordinary general meeting of 2025 to discuss the relevant proposals [7]